BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $245,804,904 | -14.8% | 3,618,507 | +2.1% | 0.03% | -14.7% |
| Q2 2023 | $288,642,910 | +4.2% | 3,544,731 | -5.3% | 0.03% | -5.6% |
| Q1 2023 | $277,019,142 | +90978.3% | 3,741,171 | +1.8% | 0.04% | -16.3% |
| Q4 2022 | $304,155 | -99.9% | 3,675,739 | +314.2% | 0.04% | +13.2% |
| Q3 2022 | $251,761,000 | -7.5% | 887,391 | +12.8% | 0.04% | -5.0% |
| Q2 2022 | $272,256,000 | -19.8% | 786,834 | +0.2% | 0.04% | -4.8% |
| Q1 2022 | $339,368,000 | -13.8% | 785,490 | +3.0% | 0.04% | -10.6% |
| Q4 2021 | $393,692,000 | +11.2% | 762,953 | +4.2% | 0.05% | -2.1% |
| Q3 2021 | $353,935,000 | +40.7% | 732,254 | +30.9% | 0.05% | +37.1% |
| Q2 2021 | $251,512,000 | +23.0% | 559,324 | +4.5% | 0.04% | +12.9% |
| Q1 2021 | $204,399,000 | +14.5% | 535,175 | -4.8% | 0.03% | +3.3% |
| Q4 2020 | $178,456,000 | +29.8% | 561,994 | +1.3% | 0.03% | +11.1% |
| Q3 2020 | $137,434,000 | -10.2% | 554,778 | -4.2% | 0.03% | -18.2% |
| Q2 2020 | $153,003,000 | +59.5% | 579,400 | +14.5% | 0.03% | +32.0% |
| Q1 2020 | $95,950,000 | -55.5% | 506,040 | -48.5% | 0.02% | +8.7% |
| Q4 2019 | $215,576,000 | +143.6% | 982,116 | +117.2% | 0.02% | +9.5% |
| Q3 2019 | $88,487,000 | -4.1% | 452,233 | +2.2% | 0.02% | -4.5% |
| Q2 2019 | $92,262,000 | +9.0% | 442,525 | +3.8% | 0.02% | 0.0% |
| Q1 2019 | $84,621,000 | -29.8% | 426,196 | -48.8% | 0.02% | +15.8% |
| Q4 2018 | $120,550,000 | +51.9% | 832,992 | +114.2% | 0.02% | -13.6% |
| Q3 2018 | $79,380,000 | +51.6% | 388,909 | +9.9% | 0.02% | +37.5% |
| Q2 2018 | $52,354,000 | +1.4% | 353,876 | +3.5% | 0.02% | -5.9% |
| Q1 2018 | $51,647,000 | +18.1% | 341,944 | +1.3% | 0.02% | +13.3% |
| Q4 2017 | $43,745,000 | +9.3% | 337,672 | +2.0% | 0.02% | 0.0% |
| Q3 2017 | $40,013,000 | +7.9% | 330,991 | +4.9% | 0.02% | 0.0% |
| Q2 2017 | $37,081,000 | +21.4% | 315,584 | +5.0% | 0.02% | +15.4% |
| Q1 2017 | $30,553,000 | +7.8% | 300,577 | +9.1% | 0.01% | 0.0% |
| Q4 2016 | $28,340,000 | +2.9% | 275,605 | +9.6% | 0.01% | -7.1% |
| Q3 2016 | $27,537,000 | -0.0% | 251,488 | +2.9% | 0.01% | -6.7% |
| Q2 2016 | $27,549,000 | +20.0% | 244,296 | +0.6% | 0.02% | +25.0% |
| Q1 2016 | $22,953,000 | +10.3% | 242,843 | +5.0% | 0.01% | 0.0% |
| Q4 2015 | $20,818,000 | +0.4% | 231,321 | +3.1% | 0.01% | -7.7% |
| Q3 2015 | $20,735,000 | -4.7% | 224,263 | +1.5% | 0.01% | +8.3% |
| Q2 2015 | $21,751,000 | +2.5% | 220,891 | +4.4% | 0.01% | 0.0% |
| Q1 2015 | $21,213,000 | +24.6% | 211,525 | +14.8% | 0.01% | +20.0% |
| Q4 2014 | $17,026,000 | – | 184,270 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |